Published in Am Rev Respir Dis on May 01, 1985
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev (1991) 7.12
The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev (2010) 4.22
Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol (2001) 4.12
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax (2007) 2.60
Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. J Clin Microbiol (1987) 2.59
Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health? Emerg Infect Dis (1998) 2.43
Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from simulated sputum specimens of patients with cystic fibrosis. J Clin Microbiol (1987) 2.31
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Subgrouping of Pseudomonas cepacia by cellular fatty acid composition. J Clin Microbiol (1989) 2.23
Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers. J Bacteriol (1995) 2.16
Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol (1993) 2.12
Specific and rapid detection by fluorescent in situ hybridization of bacteria in clinical samples obtained from cystic fibrosis patients. J Clin Microbiol (2000) 1.91
Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest (1992) 1.80
Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax (1995) 1.78
Influence of Pseudomonas aeruginosa exoproducts on virulence factor production in Burkholderia cepacia: evidence of interspecies communication. J Bacteriol (1995) 1.74
Molecular analysis of hemolytic and phospholipase C activities of Pseudomonas cepacia. Infect Immun (1990) 1.73
Purification and characterization of an extracellular protease from Pseudomonas cepacia. Infect Immun (1989) 1.70
Arbitrarily primed polymerase chain reaction as a rapid method to differentiate crossed from independent Pseudomonas cepacia infections in cystic fibrosis patients. J Clin Microbiol (1993) 1.60
The difficulties of treating cystic fibrosis in adults. J R Soc Med (1987) 1.57
Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child (1990) 1.55
Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol (1991) 1.50
Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun (1998) 1.47
Microbiology of cystic fibrosis lung infections: themes and issues. J R Soc Med (1993) 1.46
Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources. J Clin Microbiol (1988) 1.37
The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J Immunol (2008) 1.35
Identification of the mucin-binding adhesin of Pseudomonas cepacia isolated from patients with cystic fibrosis. Infect Immun (1992) 1.35
Development of a PCR probe test for identifying Pseudomonas aeruginosa and Pseudomonas (Burkholderia) cepacia. J Clin Pathol (1994) 1.33
Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child (1992) 1.31
Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax (1996) 1.29
Production of lipase by clinical isolates of Pseudomonas cepacia. J Clin Microbiol (1988) 1.25
Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation. Infect Immun (2004) 1.22
Burkholderia cepacia respiratory tract acquisition: epidemiology and molecular characterization of a large nosocomial outbreak. Epidemiol Infect (1996) 1.18
Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J Clin Invest (2004) 1.18
Burkholderia spp. alter Pseudomonas aeruginosa physiology through iron sequestration. J Bacteriol (2004) 1.13
Identification of specific antigens of Pseudomonas pseudomallei and evaluation of their efficacies for diagnosis of melioidosis. J Clin Microbiol (1993) 1.09
Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax (2002) 1.08
Pseudomonas cepacia in cystic fibrosis. Thorax (1994) 1.00
Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia. Eur J Pediatr (1998) 0.99
Cable pili and the 22-kilodalton adhesin are required for Burkholderia cenocepacia binding to and transmigration across the squamous epithelium. Infect Immun (2005) 0.98
Neutralizing monoclonal antibodies to an extracellular Pseudomonas cepacia protease. Infect Immun (1994) 0.97
Influenza-associated cystic fibrosis pulmonary exacerbations. Chest (2009) 0.97
Fimbriation of Pseudomonas cepacia. Infect Immun (1992) 0.96
Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center. J Clin Microbiol (2004) 0.96
Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia. Antimicrob Agents Chemother (1989) 0.93
Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis (2003) 0.91
Suppurative mediastinitis secondary to Burkholderia cepacia in a patient with cystic fibrosis. Can Respir J (2006) 0.83
Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation? Thorax (1997) 0.82
A possible link between infection with burkholderia bacteria and systemic lupus erythematosus based on epitope mimicry. Clin Dev Immunol (2008) 0.79
Effects of growth rate and nutrient limitation on virulence factor production in Burkholderia cepacia. J Bacteriol (1995) 0.77
Burkholderia cepacia and delta F508 homozygosity in cystic fibrosis. Arch Dis Child (1995) 0.76
Successful cessation of transmitting healthcare -- associated infections due to Burkholderia cepacia complex in a neonatal intensive care unit in a Japanese children's hospital. Eur J Med Res (2011) 0.75
Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen. Clin Infect Dis (2014) 0.75
Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet (1990) 4.39
Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet (1993) 3.17
Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis (1979) 3.02
Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest (1987) 2.97
Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. J Infect Dis (1978) 2.60
Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis (1983) 2.41
Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr (1986) 2.38
NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proc Natl Acad Sci U S A (2001) 2.33
Pneumothorax in cystic fibrosis: a 26-year experience. Ann Thorac Surg (1989) 2.23
The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol (2001) 2.18
Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis (1986) 2.10
Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest (2000) 2.05
Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med (1976) 2.04
Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis (1985) 2.04
Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition. Infect Immun (1985) 1.91
Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol (2000) 1.84
Course of cystic fibrosis in 95 patients. J Pediatr (1976) 1.78
Purification and characterization of an extracellular protease from Pseudomonas cepacia. Infect Immun (1989) 1.70
Infection with a plasmid-free variant Chlamydia related to Chlamydia trachomatis identified by using multiple assays for nucleic acid detection. J Clin Microbiol (1992) 1.66
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis (1985) 1.61
Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr (1994) 1.61
The effect of early diagnosis and treatment in cystic fibrosis: a seven-year study of 16 sibling pairs. Am J Dis Child (1977) 1.55
Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet (1975) 1.50
Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr (1984) 1.47
Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic fibrosis: Relationship to status of pulmonary disease in sibling pairs. J Pediatr (1978) 1.45
Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med (1998) 1.43
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Chemother (1984) 1.41
Granulocyte transfusions in septic adult and newborn rats: distribution of granulocytes and effect on peripheral blood and bone marrow. J Lab Clin Med (1990) 1.40
A new colorimetric nucleic acid hybridization assay for Listeria in foods. Int J Food Microbiol (1989) 1.39
Pulmonary intralobar sequestration in a patient with cystic fibrosis. Hum Pathol (1997) 1.38
Weight and menstrual function in patients with eating disorders and cystic fibrosis. Pediatrics (1990) 1.37
In vitro inhibition of lymphocyte proliferation by Pseudomonas aeruginosa phenazine pigments. Infect Immun (1983) 1.36
Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr Res (1979) 1.36
Serum bactericidal effect on Pseudomonas aeruginosa isolates from cystic fibrosis patients. Infect Immun (1981) 1.35
Symptomatic hepatic disease in cystic fibrosis: incidence, course, and outcome of portal systemic hunting. Gastroenterology (1976) 1.32
Cellular immunity to bacteria: impairment of in vitro lymphocyte responses to Pseudomonas aeruginosa in cystic fibrosis patients. Infect Immun (1977) 1.29
Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med (1996) 1.29
Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr Pulmonol (1987) 1.28
Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol (1998) 1.26
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Exercise conditioning and cardiopulmonary fitness in cystic fibrosis. The effects of a three-month supervised running program. Chest (1981) 1.25
Ultrastructure and function of alveolar macrophages from cystic fibrosis patients. Pediatr Res (1980) 1.22
Bronchial artery embolization to control hemoptysis in cystic fibrosis. Radiology (1990) 1.20
Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2000) 1.16
Treatment and prognosis of massive hemoptysis in cystic fibrosis. Am Rev Respir Dis (1978) 1.15
Open thoracotomy for pneumothorax in cystic fibrosis. Am Rev Respir Dis (1975) 1.15
Proteinases of Pseudomonas aeruginosa evoke mucin release by tracheal epithelium. J Clin Invest (1984) 1.14
An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J (2011) 1.14
Defective cellular immunity to gram-negative bacteria in cystic fibrosis patients. Infect Immun (1979) 1.14
Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother (1983) 1.12
Q-beta replicase-amplified assay for detection of Mycobacterium tuberculosis directly from clinical specimens. J Clin Microbiol (1995) 1.12
Linkage of DNA markers to cystic fibrosis in 26 families. Am J Hum Genet (1986) 1.09
Course of cystic fibrosis in black patients. J Pediatr (1976) 1.09
Decreased Cu,Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. Am J Physiol (1997) 1.08
Pseudomonas aeruginosa isolates: comparisons of isolates from campers and from sibling pairs with cystic fibrosis. Pediatr Pulmonol (1985) 1.07
Treatment and prognosis of rectal prolapse in cystic fibrosis. Gastroenterology (1982) 1.06
Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival. Chest (1999) 1.05
Performance of an automated Q-beta replicase amplification assay for Mycobacterium tuberculosis in a clinical trial. J Clin Microbiol (1997) 1.05
The pathology of fungal infection and colonization in patients with cystic fibrosis. Hum Pathol (1989) 1.04
Pathophysiologic basis for symptomatic treatment of fever. Pediatrics (1977) 1.04
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr (1986) 1.03
Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J Clin Invest (1976) 1.03
Obstructive azoospermia as a diagnostic criterion for the cystic fibrosis syndrome. Lancet (1982) 1.02
The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg (1990) 1.00
Uniparental inheritance of mitochondrial genes in yeast: dependence on input bias of mitochondrial DNA and preliminary investigations of the mechanism. Genetics (1978) 1.00
Treatment and prognosis of lobar and segmental atelectasis in cystic fibrosis. Am Rev Respir Dis (1978) 1.00
Differential induction of extracellular glutathione peroxidase and nitric oxide synthase 2 in airways of healthy individuals exposed to 100% O(2) or cigarette smoke. Am J Respir Cell Mol Biol (2000) 0.99
Beta adrenergic receptors in lymphocytes and granulocytes from patients with cystic fibrosis. J Clin Invest (1983) 0.98
Cystic fibrosis care-further considerations. Arch Dis Child (1972) 0.98
Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatr Pulmonol (1991) 0.97
Interleukin 10 (IL-10)-mediated inhibition of inflammatory cytokine production by human alveolar macrophages. Cytokine (2000) 0.97
Halothane inhibits two components of calcium current in clonal (GH3) pituitary cells. J Neurosci (1991) 0.97
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med (1987) 0.97
Nitric oxide blocks nuclear factor-kappaB activation in alveolar macrophages. Am J Respir Cell Mol Biol (1999) 0.97
Time course of hemosiderin production and clearance by human pulmonary macrophages. Chest (1984) 0.96
Correlates of psychosocial adjustment among young adults with cystic fibrosis. J Dev Behav Pediatr (1987) 0.96
Suppression of in vitro lymphocyte DNA synthesis by killed Pseudomonas aeruginosa. Infect Immun (1983) 0.95
Demonstration of adenosine receptor on human lymphocytes in vitro and its possible role in the adenosine deaminase-deficient form of severe combined immunodeficiency. Clin Immunol Immunopathol (1978) 0.94
Recreational use of psychoactive drugs by patients with cystic fibrosis. J Pediatr (1987) 0.94
Denmark to the rescue. Pediatr Pulmonol (1996) 0.94